Cargando…

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?

For years, upfront autologous hematopoietic cell transplant (auto-HCT) has been the standard of care for younger and physically fit mantle cell lymphoma (MCL) patients after chemoimmunotherapy (CIT) induction. Bruton’s tyrosine kinase (BTK) inhibitors have proven to be excellent salvage therapies, b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beitinjaneh, Amer, Kaufman, Adrienne, Wang, Yucai, Jain, Preetesh, Srour, Samer A, Wang, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Lymphoma (JL Muñoz, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557996/ https://www.ncbi.nlm.nih.gov/pubmed/36227407 http://dx.doi.org/10.1007/s11864-022-01020-9

Ejemplares similares

The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)
por: Chu, Yaya, et al.
Publicado: (2022)

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
por: Leslie, Lori A.
Publicado: (2021)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
por: Munoz, Javier L., et al.
Publicado: (2022)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider’s Perspective
por: Granroth, Ginna, et al.
Publicado: (2022)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?
por: Lee, Jessica W., et al.
Publicado: (2019)

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy
por: Sheu, Tommy, et al.
Publicado: (2018)

Poster: ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
por: Tbakhi, Bushra, et al.
Publicado: (2022)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma
por: Pinnix, Chelsea C., et al.
Publicado: (2018)

Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer
por: Guzhva, Lidia, et al.
Publicado: (2019)

Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors
por: Holtzman, Adam L., et al.
Publicado: (2019)

Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma
por: Bouard, Louise, et al.
Publicado: (2022)

Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice
por: Weber, Theresa, et al.
Publicado: (2022)

Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins
por: Li, Yijing, et al.
Publicado: (2023)

TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2022)

Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells
por: Galtier, Jean, et al.
Publicado: (2022)

Current state of CAR-T therapy for T-cell malignancies
por: Luo, Liangkui, et al.
Publicado: (2022)

Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established high-risk factors
por: Gerdtsson, Anna Sandström, et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy
por: Marangon, Miriam, et al.
Publicado: (2021)

Advances in the assessment of minimal residual disease in mantle cell lymphoma
por: Jung, Dayoung, et al.
Publicado: (2020)

EBV & lymphoma
por: Caballero, Dolores
Publicado: (2019)

Follicular lymphoma
por: Leich, Ellen
Publicado: (2019)

Understanding Long-Term Outcomes Following Sepsis: Implications and Challenges
por: Shankar-Hari, Manu, et al.
Publicado: (2016)

Follicular lymphoma genomics
por: Kumar, Emil, et al.
Publicado: (2019)

Management of post-transplant lymphoproliferative disorders
por: Dierickx, Daan, et al.
Publicado: (2019)

Treatment of high-risk follicular lymphoma
por: Jurczak, Wojciech
Publicado: (2019)

Novel prognostic tools that identify high-risk follicular lymphoma
por: Luminari, Stefano
Publicado: (2019)

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway
por: Zhang, Xiao-Yin, et al.
Publicado: (2022)

Primary Mediastinal Large B-cell Lymphoma
por: Dabrowska-Iwanicka, Anna, et al.
Publicado: (2014)

Smudge cells in CD200(+), TP53 mutated leukemic mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2022)

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
por: Albanyan, Omar, et al.
Publicado: (2022)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation
por: Shanbhag, Satish, et al.
Publicado: (2010)

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes
por: Wagner, Charlotte B., et al.
Publicado: (2023)

New Biomarkers in Anaphylaxis (Beyond Tryptase)
por: Galvan-Blasco, P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lqsaimdl3pl876tc5hrhh82ns7